anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
BACKGROUND: Pathogenic variants in the zinc finger protein coding genes are rare causes of intellectual disability and congenital malformations. Mutations in the ZNF148 gene causing GDACCF syndrome (global developmental delay, absent or hypoplastic corpus callosum, dysmorphic facies; MIM #617260) have been reported in five individuals so far.
METHODS: As a result of an international collaboration using GeneMatcher Phenome Central Repository and personal communications, here we describe the clinical and molecular genetic characteristics of 22 previously unreported individuals.
RESULTS: The core clinical phenotype is characterised by developmental delay particularly in the domain of speech development, postnatal growth retardation, microcephaly and facial dysmorphism. Corpus callosum abnormalities appear less frequently than suggested by previous observations. The identified mutations concerned nonsense or frameshift variants that were mainly located in the last exon of the ZNF148 gene. Heterozygous deletion including the entire ZNF148 gene was found in only one case. Most mutations occurred de novo, but were inherited from an affected parent in two families.
CONCLUSION: The GDACCF syndrome is clinically diverse, and a genotype-first approach, that is, exome sequencing is recommended for establishing a genetic diagnosis rather than a phenotype-first approach. However, the syndrome may be suspected based on some recurrent, recognisable features. Corpus callosum anomalies were not as constant as previously suggested, we therefore recommend to replace the term 'GDACCF syndrome' with 'ZNF148-related neurodevelopmental disorder'.
Participants will receive a single dose of bedaquiline in 3 subsequent sessions as bedaquiline oral test tablet 1 under fasted condition (Treatment B) in period 1, followed by bedaquiline oral reference tablet under fasted condition (Treatment A) in period 2, thereafter will receive bedaquiline oral test tablet 1 under fed condition (Treatment E) in period 3. Each treatment period will be separated with a washout period of at least 28 days.
Grup P will not take vitamin D during 12 weeks. This group just only will follow by researchers.At first day end end of the 12 weeks serum vitamin D level will analyse with laboratory testing.End of the 12 weeks, the children will be perform dental treatment under general anaesthesia. Postoperative pain, anxiety and sedation will evaluate.
HEMLIBRA is intended for use under the guidance of a healthcare provider. After proper training in subcutaneous injection technique, a patient may self-inject, or the patient's caregiver may administer HEMLIBRA, if a healthcare provider determines that it is appropriate. Self-administration is not recommended for children less than 7 years of age. The HEMLIBRA "Instructions for Use" contains more detailed instructions on the preparation and administration of HEMLIBRA [see Instructions for Use].

  * Visually inspect HEMLIBRA for particulate matter and discoloration before administration. HEMLIBRA for subcutaneous administration is a colorless to slightly yellow solution. Do not use if particulate matter is visible or product is discolored.
  * A syringe, a transfer needle with filter and an injection needle are needed to withdraw HEMLIBRA solution from the vial and inject it subcutaneously.
  * Refer to the HEMLIBRA "Instructions for Use" for handling instructions when combining vials. Do not combine HEMLIBRA vials of different concentrations (i.e. 30 mg/mL and 150 mg/mL) in a single injection.



Please see below the selection criteria for the recommended device options:

  * Administer doses of HEMLIBRA up to 1 mL with a 1 mL syringe. A 1 mL syringe fulfilling the following criteria may be used: Transparent polypropylene or polycarbonate syringe with Luer-Lock tip, graduation 0.01 mL, sterile, for injection only, single-use, latex-free and non-pyrogenic, commercially available in the US.
  * Administer doses of HEMLIBRA greater than 1 mL and up to 2 mL with a 2 mL or 3 mL syringe. A 2 mL or 3 mL syringe fulfilling the following criteria may be used: Transparent polypropylene or polycarbonate syringe with Luer-Lock tip, graduation 0.1 mL, sterile, for injection only, single-use, latex-free, and non-pyrogenic, commercially available in the US.
  * A transfer needle with a filter fulfilling the following criteria should be used: Stainless steel needle with Luer-Lock connection, sterile, 18 gauge, length 1 to 1½ inch, single bevel or semi-blunted tip, single-use, latex-free, containing a 5-micron filter and non-pyrogenic, commercially available in the US.
  * An injection needle fulfilling the following criteria may be used: Stainless steel with Luer-Lock connection, sterile, 26 gauge (acceptable range: 25 – 27 gauge), length preferably ⅜ inch or maximal length ½ inch, single-use, latex-free and non-pyrogenic, including needle safety feature, commercially available in the US.
  * Administer each injection at a different anatomic location (upper outer arms, thighs, or any quadrant of abdomen) than the previous injection. An injection should never be given into moles, scars, or areas where the skin is tender, bruised, red, hard, or not intact. Administration of HEMLIBRA in the upper outer arm should only be performed by a caregiver or healthcare provider.
  * Discard any unused HEMLIBRA remaining in the single-dose vial.
BELBUCA contains buprenorphine, a Schedule III controlled substance. As an opioid, BELBUCA exposes users to the risks of addiction, abuse, and misuse [see Drug Abuse and Dependence (9)].

Although the risk of addiction in any individual is unknown, it can occur in patients appropriately prescribed BELBUCA. Addiction can occur at recommended dosages and if the drug is misused or abused.

Assess each patient's risk for opioid addiction, abuse, or misuse prior to prescribing BELBUCA and reassess all patients receiving BELBUCA for the development of these behaviors and conditions. Risks are increased in patients with a personal or family history of substance abuse (including drug or alcohol abuse or addiction) or mental illness (e.g., major depression). The potential for these risks should not, however, prevent the proper management of pain in any given patient. Patients at increased risk may be prescribed opioids such as BELBUCA but use in such patients necessitates intensive counseling about the risks and proper use of BELBUCA, along with frequent reevaluation for signs of addiction, abuse, or misuse. Consider prescribing naloxone for the emergency treatment of opioid overdose [see Dosage and Administration (2.2), Warnings and Precautions (5.2)].

Abuse or misuse of BELBUCA by swallowing may cause choking, overdose, and death [see Overdosage (10)].

Opioids are sought for nonmedical use and are subject to diversion from legitimate prescribed use. Consider these risks when prescribing or dispensing BELBUCA. Strategies to reduce the risk include prescribing the drug in the smallest appropriate quantity and advising the patient on careful storage of the drug during the course of treatment and the proper disposal of unused drug. Contact local state professional licensing board or state-controlled substances authority for information on how to prevent and detect abuse or diversion of this product.
p53 is a tumor suppressor gene activated in response to cellular stressors that inhibits cell cycle progression and induces pro-apoptotic signaling. The protein level of p53 is well balanced by the action of several E3 ligases and deubiquitinating enzymes (DUBs). Several DUBs have been reported to negatively regulate and promote p53 degradation in tumors. In this study, we identified USP19 as a negative regulator of p53 protein level. We demonstrate a direct interaction between USP19 and p53 by pull down assay. The overexpression of USP19 promoted ubiquitination of p53 and reduced its protein half-life. We also demonstrate that CRISPR/Cas9-mediated knockout of USP19 in cervical cancer cells elevates p53 protein levels, resulting in reduced colony formation, cell migration, and cell invasion. Overall, our results indicate that USP19 negatively regulates p53 protein levels in cervical cancer progression.
Ageism in healthcare has received increased attention in recent years, but literature focusing on how it affects individuals living with rare diseases remains scant. The rare disease population already faces obstacles when navigating health systems, and ageism has the potential to exacerbate existing health inequities. We conducted a systematic review of peer-reviewed and gray literature on health inequities in rare disease populations, seeking to identify publications that reported primary or secondary data on the equitable or inequitable treatment of these populations, or that discussed related regulatory, moral, or philosophical issues. Our aims were to understand how health inequities in these populations arise, how they are justified from societal points of view, how they manifest themselves in laws and regulations, and what effects they have on health care access and health outcomes. We retrieved information from 63 publications, which we inductively synthesized into five categories: ethical discussions, societal preferences, regulations, access to care, and health outcomes. Integrating insights from these categories, we developed an Ethical Spectrum and Resource Allocation Framework, which explains the emergence of equity issues and how they are manifested in health systems. By providing a better understanding of the root causes of health inequities, particularly among older adults, the framework can inform health policymaking, improving access to care and health outcomes for rare disease patients.
The invention discloses an aurone compound, and a preparation method and application thereof. The aurone compound is extracted from aromatic tobacco, the 4' site is acetyl, the structural formula is shown in the specification, and the aurone compound is named as 4'-acetyl-5-hydroxy-6-methoxy aurone. The preparation method of the aurone compound comprises the following steps: treating raw materials, performing ultrasonic extraction, performing silica gel column chromatography, separating through high pressure liquid chromatography, and performing gel column chromatography. The aurone compound is applicable to the preparation of medicaments for resisting leukemia cells and/or human breast cancer cells. The aurone compound disclosed by the invention is separated out from aromatic tobacco for the first time, and the molecular formula and structure of the aurone compound can be confirmed. According to the invention, ethanol is used as solvent, thereby causing less environmental pollution, and ensuring high safety and environment friendliness; and the compound is simple in structure and easy to artificially synthesize. The compound has obvious inhibiting effect on leukemia cells (NB4) and human breast cancer cells (MCF7), and the IC50 values are respectively 2.6mu M and 1.8mu M, thus indicating that the aurone compound can be used as a lead compound of anticancer medicaments.
Systems and methods for rapidly and reliably determining an arch with of a patient's dental arch. A first portion of a 3D model of a patient's dentition is identified that corresponds to a first target tooth, the first portion of the 3D model is associated with one or more attributes of the first target tooth. A second portion of the 3D model is identified that corresponds to a second target tooth opposing the first target tooth. The second portion is associated with one or more attributes of the second target tooth. The arch width is automatically measured based on the attributes of the first and second target teeth. A graphic representing the arch width is overlayed on the patient's dentition.
This 12-year cohort study of 80 long-term non-progressors (LTNPs) observed a cumulative follow-up duration of 628.5 person-years. Among them, 60 received antiretroviral therapy (ART) for a total of 418.6 person-years. Twenty-four deaths occurred during the follow-up period, with an average age of 42.36 years and a lowest 8-year survival rate of 0.90. Cox model analysis revealed that the risk of AIDS-related death was 1.47 times higher for non-marital, non-commercial heterosexual transmission than for injection drug use. Treatment initiation at ages 31-40 was correlated with an elevated risk of mortality, while treatment for 3-10 years reduced mortality risks in untreated LTNPs. Flow cytometry observed significant differences in the proportion of NK cells. Long-term ART (> 2 years) before LTNPs developed AIDS symptoms could lower mortality risk and potentially extend lifespan, especially when it was initiated at a younger age without affecting NK cell balance. Epidemiological and immunological studies on ART-treated LTNPs are vital for advancing HIV treatment and achieving functional cures for AIDS individuals.
An implantable electrical stimulating device and system provides for a remote determination of the identity of the person in whom the stimulating device is implanted. The stimulating device may be a pacemaker, a defibrillator, another medical device or a non-medical device. The bases for the remote identification are (1) the comingling of (A) biologic identification information of the person linked to the stimulating device, and (B) information pertaining to a physiologic parameter (e.g. heart rate information) of that person, and (2) the modulation of the physiologic parameter by external information. Embodiments of the invention in which the stimulating device is external to the person are possible. By utilizing the apparatus providing for the remote identification of a person plus stimulating device, one aspect of secure communication—that based on reliable mutual identification of each participant in a communication—is achieved.
Ten percent of patients account for up to 70% of acute care costs. Among these "super-utilizer" patients, homelessness is a robust social determinant of acute care utilization. Through a field-based dashboard and clinical aids, the Hot Spotter Analytic program assists Patient Aligned Care Teams (PACT) with targeting and tailoring care for the highest-need homeless Veterans. However, many Veterans identified by the Analytics do not engage in supportive services that reduce risk for acute care utilization. Peer Specialists (PS) are a high-value workforce that can facilitate Veterans' engagement in care. Yet, there is a need to enhance the PS role with a structured approach that can capitalize on known facilitators of care engagement among homeless Veterans. Whole Health Coaching (WHC) is one such approach. By focusing on patients' values and goals rather than treatment of specific conditions, WHC reduces patients' stigma regarding their care needs and increases patient activation and well-being, which can increase engagement in supportive services.

The goal of this project is to integrate use of Hot Spotter Analytics with Peer Specialists trained in Whole Health Coaching (PS-WHC) and evaluate whether this approach reduces homeless Veterans' frequent use of acute care. Using a Hybrid Type 1 design at the Palo Alto, Bedford, and North Little Rock VAs, the investigators will test whether receipt of PS-WHC (vs. Enhanced Usual Care; EUC) predicts (1a) lower acute care utilization, (1b) better health-related outcomes, and whether (1c) the effects of PS-WHC on 1a and 1b are mediated by increased (i) patient activation and well-being, and (ii) access to supportive services. Aim 2: Conduct a process evaluation to inform VA's potential widespread implementation of Hot Spotter Analytics + PS-WHC on PACTs. Aim 3: Conduct a Budget Impact Analysis to determine the impact on total costs of VA care due to implementing PS-WHC.
The invention relates to the technical field of microorganisms, in particular to a microorganism strain with anti-tumor cell activity and broad-spectrum antibacterial activity. Paraconiothyrium sp. YM311593 is now collected in a collection unit specified by the State Intellectual Property Office, and has the collection number of CCTCC NO: M 2013142. A paraconiothyrium endophytic fungus is separated and obtained from azadirachta indica for the first time, and the paraconiothyrium sp. YM311593 is found to have obvious growth inhibition activity on four tumor cells and have relatively obvious growth inhibition effect on nine pathogenic microorganisms, namely two human body pathomycetes, four plant pathogenic fungi, two gram positive bacteria and a gram negative bacterium. The invention aims at utilizing endophytic fungus resources of a plant to obtain novel natural active ingredients of anti-tumor or antibacterial agents through fermentation.
BACKGROUND: Standard treatment for early-stage or locoregionally advanced non-small cell lung cancer (NSCLC) includes surgical resection. Recurrence after surgery is commonly reported, but a summary estimate for postsurgical recurrence-free survival (RFS) in patients with NSCLC is lacking.
RESEARCH QUESTION: What is the RFS after surgery in patients with stage I-III NSCLC at different time points, and what factors are associated with RFS?
STUDY DESIGN AND METHODS: A systematic search was performed in MEDLINE, EMBASE, and Cochrane databases between January 2011 and June 2021. The primary outcome was RFS at 1, 2, 3, and 5 years postresection. Single-arm, random-effects meta-analyses were done to calculate effect estimates and 95% CIs. Analyses were stratified by stage/substage as per the AJCC Cancer Staging Manual, and RFS was estimated (1) after pooling studies, using seventh or eighth edition staging criteria; and (2) among studies using only the eighth edition. Meta-regressions were performed to assess associations between RFS and patient demographic/clinical characteristics of interest.
RESULTS: Data from 471 studies comprising 1,060 surgical study arms were extracted. RFS estimates from 60,695 patients staged with the seventh or eighth edition were analyzed. RFS ranged from 96% at 1 year postresection to 82% at 5 years for stage I, and from 68% at 1 year to 34% at 5 years for stage III. Estimates for patients staged using only eighth edition criteria were slightly higher. Older age, higher percentage of male patients, advancing stage, larger tumor size, and geographic region (North America/Europe vs Asia) were significantly associated with worse RFS.
INTERPRETATION: This study presents a comprehensive assessment of reported RFS from published clinical literature, offering estimates at multiple postsurgical time points and by geographic region. Findings can inform treatment decisions, clinical trial design, and future research to improve outcomes among patients with NSCLC.
This infographic accompanies the editorial which critically evaluates how hip-related pain is currently managed, highlighting the limitations of traditional biomedical interventions alone in restoring optimal function and well-being. Psychological factors are key determinants of outcomes after surgical and nonsurgical treatment. We highlight the need for a holistic, patient-centered approach in evaluating and treating hip-related pain. Shifting to a holistic, patient-centered approach can improve treatment outcomes and reduce patient suffering. We guide readers to the impact of psychological factors on treatment outcomes, provide clinical considerations for how clinicians might approach psychologically informed practice, and outline future research directions. J Orthop Sports Phys Ther 2024;54(8):573. doi:10.2519/jospt.2024.9003.
NEW MATERIAL:A compound expressed by formula I (R1 is 8-20C long-chain alkyl, resin acid side chain, etc,; R2 is side chain of constituent amino acid of casein-derived polypeptide; n is an integer of 3-20; M is H, onium of alkali metal, etc.) or salt thereof USE:An additive for hairdressing cosmetics, e.g. shampoo, rise, etc., principal ingredient in cosmetics, e.g. lotion, etc., having excellent surface-active action and mild action as well as protecting action on the skin or hair, regenerating action on damaged hair, etc., with hardly any irritation to the skin and mucosae. PREPARATION:For example, cow's mild casein is dissolved in an aqueous solution in a high concentration, e.g. urea, etc., and hydrolyzed with a proteolytic enzyme, e.g. pepsine, etc., at 30-45 deg.C for 3-24hr. An acid chloride derivative of a higher fatty acid expressed by formula III is added to an aqueous solution of the resultant casein-deived polypeptide expressed by formula II which stirring at pH 8-10 to acylate the compound expressed by formula II.
PURPOSE:To provide the titled tablet containing glucomannan as an active component, having moderate hardness, disintegration time, and the content of the main component by the addition of a specific binder, useful for the prevention and remedy of constipation and obesity, and stable with time. CONSTITUTION:A glucomannan-containing tablet having a glucomannan content of >=30%, a hardness of >=5kg, and a disintegration time of <=3min. Glucomannan is a polysaccharide composed of glucose and mannose and having a molecular weight of about 2,000,000 and a polymerization degree of about 12,000, and has been administered in the form of granules for the prevention and remedy of constipation and obesity. The disavantage of the drug is unagreeable feeling in administration. Since glucomannan has high water-absorptivity, it is difficult to tablet by conventional compression molding technique. A tablet stable with time and having moderately high hardness to endure the treatment such as coating, etc. can be obtained by using a binder based on concentrated solution of saccharides, inorganic salts, etc.
PURPOSE:To carry out the titled test, by administering an animal with the drug to be tested and a calcium agent for calcium-setting, and then with a triggering agent, and examining the reaction in the myocardium of the animal. CONSTITUTION:An experimental animal (e.g. rabbit, dog, etc.) is administered with definite amounts of the drug to be tested and a calcium agent for calcium- setting (e.g. a solution containing calcium chloride as at least a component) for a definite time interval (e.g. 2-6% aqueous solution of calcium chloride is administered at a rate of 1.4-0.1ml/min for about 2-3hr according to the concentration). The animal is then administered with a triggering agent (e.g. a solution containing calcium chloride as at least a component, a solution containing caffeine as at least a component, etc.), and the reaction in the myocardium of the animal is examined to test the suitability of said drug as a preventive or remedy for acute myocardial infarction.
This arm is a self-directed, multicomponent, exercise intervention. Participants exercise on their own and follow a progressive stepped program that occurs in the following order: cardiorespiratory exercises, flexibility exercises, strength (upper and lower body) exercises, and balance exercises. Participants also complete a daily log of their exercises and return the logs every week for 12 weeks.
Subjects were to be enrolled until there were at least 30 evaluable subjects (of whom at least 60% were \<7 years of age). Evaluable subjects were those who completed 3 Visual analogue scale (VAS), 1 for each of the 3 tasting steps with the 3 flavoured oral suspensions.
Propranolol is a nonselective, beta-adrenergic receptor-blocking agent possessing no other autonomic nervous system activity. It specifically competes with beta-adrenergic receptor-stimulating agents for available receptor sites. Of the 2 enantiomers of propranolol, the S-enantiomer blocks beta-adrenergic receptors. When access to beta-receptor sites is blocked by propranolol, chronotropic, inotropic, and vasodilator responses to beta-adrenergic stimulation are decreased proportionately. At dosages greater than required for beta-blockade, propranolol also exerts a quinidine-like or anesthetic-like membrane action, which affects the cardiac action potential. The significance of the membrane action in the treatment of arrhythmias is uncertain.